LKT Laboratories, Inc.

CCT-128930

Phone: 888-558-5227
651-644-8424
Fax: 888-558-7329
Email: getinfo@lktlabs.com
Web: lktlabs.com

Product Information

Product ID C1176
CAS No. 885499-61-6
Chemical Name 4-(4-Chlorobenzyl)-1-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-4-piperidinamine
Synonym CCT128930



Formula $C_{18}H_{20}ClN_5$
Formula Wt. 341.84
Melting Point
Purity ≥98%
Solubility

DMSO	68 mg/mL
Ethanol	6 mg/mL
Water	Insoluble

Bulk quanitites available upon request

Product ID	Size
C1176	1 mg
C1176	5 mg
C1176	10 mg
C1176	25 mg

Store Temp -20°C
Ship Temp Ambient
Description CCT-128930 is a pyrrolopyrimidine that inhibits Akt and exhibits anticancer chemotherapeutic activity. In hepatoma cancer cells, this compound induces G1 phase cell cycle arrest, apoptosis, and autophagy, upregulates expression of p21, p27, and p53, and suppresses cell proliferation. CCT-128930 also induces G1 phase cell cycle arrest in glioblastoma cells and limits tumor growth in animal models with breast cancer xenografts.

References

Wang FZ, Chang ZY, Fei HR, et al. CCT128930 induces cell cycle arrest, DNA damage, and autophagy independent of Akt inhibition. Biochimie. 2014 Aug;103:118-25. PMID: 24793486.

Yap TA, Walton MI, Hunter LJ, et al. Preclinical pharmacology, antitumor activity, and development of pharmacodynamic markers for the novel, potent AKT inhibitor CCT128930. Mol Cancer Ther. 2011 Feb;10(2):360-71. PMID: 21191045.

Caldwell JJ, Davies TG, Donald A, et al. Identification of 4-(4-aminopiperidin-1-yl)-7H-pyrrolo[2,3-d]pyrimidines as selective inhibitors of protein kinase B through fragment elaboration. J Med Chem. 2008 Apr 10;51(7):2147-57. PMID: 18345609.